Showing results (1261-1270 of 10,079) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|February 1, 2020
Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?Raffaela Rametta, Anna L Fracanzani, Silvia Fargion, et al.Current Pharmaceutical Design|February 1, 2020
Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A ReviewSeyed H Shahcheraghi, Venant Tchokonte-Nana, Marzieh Lotfi, et al.Current Pharmaceutical Design|January 30, 2020
A Hidden Human Proteome Signature Characterizes the Epithelial Mesenchymal Transition ProgramDaniele Vergara, Tiziano Verri, Marina Damato, et al.Current Pharmaceutical Design|February 1, 2020
Dysmetabolic Iron Overload in Metabolic SyndromeAlexandros Sachinidis, Michael Doumas, Konstantinos Imprialos, et al.Current Pharmaceutical Design|January 20, 2019
Human Mesenchymal Stem Cell-derived Exosomes Reduce Ischemia/Reperfusion Injury by the Inhibitions of Apoptosis and AutophagyXiaofei Jiang, Kar-Sheng Lew, Qiying Chen, et al.Current Pharmaceutical Design|January 20, 2019
Recent Advances on Cytotoxic Sesquiterpene LactonesJosé Quintana, Francisco EstévezCurrent Pharmaceutical Design|January 15, 2019
The Prognostic and Predictive Value of microRNAs in Patients with H. pylori-positive Gastric CancerSeyed Mostafa Parizadeh, Reza Jafarzadeh-Esfehani, Amir Avan, et al.Current Pharmaceutical Design|January 15, 2019
Anticancer Hybrid Combinations: Mechanisms of Action, Implications and Future PerspectivesEva M Domínguez-Martín, Ana M Díaz-Lanza, Célia M C FaustinoCurrent Pharmaceutical Design|January 15, 2019
Natural Products Inspired Modulators of Cancer Stem Cells-specific Signaling Pathways Notch and HedgehogRocco Palermo, Francesca Ghirga, Maria Grazia Piccioni, et al.Pageof 1,008